COMMUNIQUÉS West-GlobeNewswire

Journal of Analytical Toxicology Publishes Peer-Reviewed Validation Study Demonstrating Accuracy of Omega Laboratories’ Test Method for Detecting Marijuana in Breath Samples Using Cannabix Technologies’ Breath Collection Unit
03/03/2026
VANCOUVER, British Columbia, March 03, 2026 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTCID: BLOZF) (Frankfurt: 8CT) (the “Company” or “Cannabix”) and Omega Laboratories Inc (“Omega”) proudly announce [...]
Paris Hilton Shares Her Experience with JORNAY PM and Launches New 'Embrace Your Sparkle' Campaign with Collegium to Empower the ADHD Community
03/03/2026
– Paris Hilton shares her personal ADHD journey and encourages others to see ADHD in a new light – – Together, Paris and Collegium are reframing common stereotypes and highlighting experiences that are often part of [...]
Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders
03/03/2026
Oak Ridge, TN, March 03, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology today issued a corporate update in a Letter to Shareholders filed in its [...]
TOMI Environmental Solutions Appoints Total Clean Air as Preferred European Partner for SteraMist iHP Decontamination Technology
03/03/2026
Strategic Partnership Strengthens UK and EU GMP Annex 1 Compliance FREDERICK, Md., March 03, 2026 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc. ® (“TOMI”) (NASDAQ: TOMZ), a global leader in disinfection and [...]
Acumen Pharmaceuticals to Showcase Advances in Alzheimer's Treatment at International Conference on Alzheimer’s and Parkinson’s Diseases 2026
03/03/2026
NEWTON, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs [...]
Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran (lonvo-z); Hereditary Angioedema (HAE) Patient-Focused Research at AAAAI 2026
03/03/2026
Presentations include three-year follow-up data from patients receiving a one-time 50 milligram (mg) dose of lonvo-z and survey findings highlighting patients’ continued treatment burden and unmet needs CAMBRIDGE, Mass [...]
Rein Therapeutics Doses First Patient in Phase 2 Trial of LTI-03 for Idiopathic Pulmonary Fibrosis
03/03/2026
Randomized, placebo-controlled study to evaluate safety, tolerability, and potential for positive impact on lung function AUSTIN, Texas, March 03, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a [...]
Nanox Signs Distribution Agreement with Imperial Imaging Technology to Expand Nanox.ARC Access Across U.S. Southeast
03/03/2026
Agreement with Imperial Imaging strengthens Nanox’s commercial rollout across the orthopedic-rich segment in six U.S. Southeast states. Distribution Agreement Supports U.S. Market Expansion PETACH TIKVA, Israel, March [...]
Cirrus Therapeutics Announces Strategic Expansion to Singapore and Other Key Updates Supporting its Growth as a Leading Global Ocular Immunology Company
03/03/2026
Expands global footprint to Singapore, gaining access to Asia-Pacific region to support research, clinical development and partnering activities Forms strategic partnership with A*STAR to accelerate advancement of [...]
Neuronetics to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call
03/03/2026
MALVERN, Pa., March 03, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc., (NASDAQ: STIM) (the “Company” or “Neuronetics”), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic [...]
INVO Fertility’s Wisconsin Clinic Joins Progyny Network
03/03/2026
INVO’s Wisconsin Clinic is now in-network for Progyny members, expanding the clinic’s market reach MIDDLETON, Wis. and SARASOTA, Fla., March 03, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO [...]
Daxor Corporation Reports 2025 Fiscal Year Results: Operating Revenue Up 45%, Net Asset Value Rises to $9.07 Per Share
03/03/2026
Strategic Realignment to Clinical Growth Supported by FDA 510(k) Clearance for Next-Generation Blood Volume Analyzer Oak Ridge, TN, March 03, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader [...]
Annovis Announces Two Presentations at the AD/PD™ 2026 International Conference
03/03/2026
MALVERN, Pa., March 03, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for [...]
Prime Medicine Reports Full Year 2025 Financial Results and Provides Business Updates
03/03/2026
-- On track to file IND and/or CTA for Wilson Disease and AATD programs in 1H 2026 and mid-2026, respectively; initial clinical data for both expected in 2027 -- -- Ongoing engagement with FDA for PM359 in CGD; plan to [...]
Hepion Pharmaceuticals In-Licenses ctRNA Biomarker Assay to Facilitate Early Diagnosis and Surveillance of Hepatocellular Carcinoma
03/03/2026
Next-generation, non-invasive diagnostic platform has potential applications in solid tumor types beyond liver cancer Licensing deal reflects Hepion’s strategic shift to advancing clinically proven liquid biopsy tests [...]
T-knife Therapeutics Announces Authorization of Clinical Trial Application for TK-6302, A Multi-Armored, CRISPR based T cell Therapy for Solid Tumors
03/03/2026
- Phase 1 ATLAS trial to evaluate TK-6302 in patients with advanced PRAME-positive solid tumors authorized for initiation SAN FRANCISCO and BERLIN, March 03, 2026 (GLOBE NEWSWIRE) -- T-knife Therapeutics, Inc., a [...]
Orchestra BioMed Announces Presentations Highlighting AVIM Therapy Potential Impact on Hypertensive Heart Disease and Heart Failure at THT and CRT
03/03/2026
NEW HOPE, Pa., March 03, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through [...]
Propanc Biopharma’s Lead Asset PRP Shows >85% Tumor Growth Inhibition in Preclinical Pancreatic Models
03/03/2026
PRP May Outshine Traditional Therapies in a Booming $4.4 Billion Market MELBOURNE, Australia, March 03, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical [...]
Resmed’s Global Sleep Survey Reveals Sleep is One of the Top Health Priorities, but Quality Rest Remains Out of Reach
03/03/2026
Insights from 30,000 people across 13 countries show global sleep health awareness is growing, yet an action gap remains 53% of people surveyed rank sleep as the most important behavior for a long, healthy life, ahead [...]

Pages